Experimental and Clinical Psychopharmacology
October 22, 2026
C Austin Zamarripa, Tory R Spindle, Dustin C Lee et al.
Co-use of smoked/vaped tobacco and cannabis is increasing with expanding legalization, yet controlled clinical studies examining mechanisms underlying co-use remain limited. This study evaluated whether acute smoked cannabis influences subsequent use ("chasing") of combustible cigarettes and e-cigarettes among people who use cannabis, cigarettes, and e-cigarettes. Twenty adults who used...
Zenodo (CERN European Organization for Nuclear Research)
September 17, 2026
Dustin C Lee
preprint
This paper advances a single, unambiguous thesis: artificial intelligence systems cannot experience fear. Not now, not in any foreseeable future, and not for reasons that better hardware or more sophisticated software will resolve. Fear is not a computation. It is not a software feature awaiting implementation. It is a neurobiological cascade — amygdala activation,...
Neuropsychopharmacology
November 1, 2025
Justin C Strickland, Hayleigh E Tilton, Noah M Patton et al.
Cannabis products premixed with caffeine are increasingly present in the United States marketplace. Despite emergence of this product class, no human laboratory data have directly evaluated the isolated impact of caffeine on Δ9-tetrahydrocannabinol (Δ9-THC) effects as well as additional impacts of other common co-administered cannabinoids. This double-blind, randomized, placebo-controlled,...
JAMA Psychiatry
2023
Brian D Kiluk, Bethea A Kleykamp, Sandra D Comer et al.
22 citations
Novel treatments for opioid use disorder (OUD) are needed to address both the ongoing opioid epidemic and long-standing barriers to existing OUD treatments that target the endogenous μ-opioid receptor (MOR) system. The goal of this review is to highlight unique clinical trial design considerations for the study of emerging treatments for OUD that address targets beyond the MOR system. In...
Drug and Alcohol Dependence
June 1, 2018
Nicolas J. Schlienz, Dustin C Lee, Maxine L Stitzer et al.
There is a clear need for advancing the treatment of cannabis use disorders. Prior research has demonstrated that dronabinol (oral THC) can dose-dependently suppress cannabis withdrawal and reduce the acute effects of smoked cannabis. The present study was conducted to evaluate whether high-dose dronabinol could reduce cannabis self-administration among daily users. Non-treatment seeking daily...